Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2020

01-08-2020 | Brachytherapy | Research Article

Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?

Authors: Y. Zhang, C. Ascaso, A. Herreros, J. Sánchez, M. del Pino, A. Torné, Y. Li, S. Sabater, M. Arenas, A. Biete, Á. Rovirosa

Published in: Clinical and Translational Oncology | Issue 8/2020

Login to get access

Abstract

Purpose

To determine whether brachytherapy with a single hypofractionated dose of 7 Gy provides the similar vaginal-cuff relapses and safety profile in terms of complications compared to schedules of 2 or 3 fractions of lower doses in patients treated previously with external beam irradiation in postoperative endometrial carcinoma.

Methods/material

From June 2003 to December 2016, 325 patients were treated with 3 different schedules of high-dose-rate brachytherapy after external beam irradiation for postoperative endometrial carcinoma. The patients were divided into 3 groups: Group-1: 125 patients were treated with 3 fractions of 4–6 Gy per fraction (3 fractions/week) between 2003 and 2008; Group-2: 93 patients were treated with 2 consecutive daily fractions of 5–6 Gy between 2008 and 2011; Group-3: 107 patients received a single fraction of 7 Gy between 2011 and 2016. Bladder and rectum complications were assessed using RTOG scores and with the objective scores of LENT-SOMA for the vagina. Statistics: the chi-square test.

Results

The mean follow-up of Groups 1, 2 and 3 was 95, 67 and 51 months, respectively. Three patients in Group-1, 2 in Group-2, 1 in Group-3 developed vaginal-cuff relapse (p = 0.68). No differences were found in late toxicity among the three groups.

Conclusions

One single dose of 7 Gy is safe and effective and may be the best treatment schedule with a similar incidence of vaginal-cuff relapses, complications and patient comfort with less hospital attendance.
Literature
1.
Rauh-Hain JA, Pepin KJ, Meyer LA, Clemmer JT, Lu KH, Rice LW, et al. Management for elderly women with advanced stage, high-grade endometrial cancer. Obstet Gynecol. 2015;126(6):1198–206.CrossRef
2.
3.
Guinot JL, Perez-Calatayud J, Azcoaga JM, Herruzo I, Bodineau C, Rovirosa A, et al. Consensus on treatment of endometrium carcinoma with brachytherapy. Clin Transl Oncol. 2012;14:263–70.CrossRef
4.
Meyer LA, Bohlke K, Powell MA, Fader AN, Franklin GE, Lee LJ, et al. Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for radiation oncology evidence-based guideline. J Clin Oncol. 2015;33(26):2908–13.CrossRef
5.
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Lancet. 2010;375:816–23.CrossRef
6.
7.
Mitra D, Klopp AH, Viswanathan AN. Pros and cons of vaginal brachytherapy after external beam radiation therapy in endometrial cancer. Gynecol Oncol. 2016;140:167–75.CrossRef
8.
Rovirosa A, Ascaso C, Sánchez-Reyes A, Herreros A, Abellana R, Pahisa J, et al. Three or four fractions of 4–5Gy per week in postoperative high-dose-rate brachytherapy for endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2011;8:418–23.CrossRef
9.
Nag S, Erickson B, Parikh S, Gupta N, Varia M, Glasgow G. The American brachytherapy society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 2000;48(3):779–90.CrossRef
10.
Harkenrider MM, Grover S, Erickson BA, Viswanathan AN, Small C, Kliethermes S, et al. Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy Society. Brachytherapy. 2016;15(1):23–9.CrossRef
11.
Harkenrider MM, Block AM, Alektiar KM, Gaffney DK, Jones E, Klopp A, et al. American Brachytherapy Task Group Report: adjuvant vaginal brachytherapy for early-stage endometrial cancer: a comprehensive review. Brachytherapy. 2017;16(1):95–108.CrossRef
12.
Rovirosa A, Ascaso C, Arenas M, Sabater S, Herreros A, Camarasa A, et al. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules. Radiother Oncol. 2015;116:143–8.CrossRef
13.
Rovirosa A, Cortes K, Ascaso C, Herreros A, Sánchez J, Arenas M, et al. Comparative results of vaginal relapses and toxicity of three 192-Ir HDR brachytherapy (BT) schedules in postoperative endometrial carcinoma (EC). Int J Radiat Oncol Biol Phys. 2017;99(25suppl.2):E309 (Abstract).CrossRef
14.
Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma prospective randomized study. Int Radiat Oncol Biol Phys. 2012;82:1249–55.CrossRef
15.
Creasman W. Revised FIGO staging for carcinoma of endometrium. Int J Gynaecol Obstet. 2009;105:109.CrossRef
16.
ICRU Report no. 38, dose and volume specification for reporting intracavitary therapy in gynaecology. In: Chassagne D, Dutreix A, Almond P, editors. International Commission on Radiation Units & Measurements, Inc.: Bethesda, USA.1985. https://​icru.​org/​icru-news/​page-10.
17.
Rovirosa A, Herreros A. MRI-based evaluation of the vaginal-cuff in brachytherapy planning. Int J Radiat Oncol Biol Phys. 2016;95(4):1317–21 (In Regard to Chapman et al.).CrossRef
18.
19.
Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. Cochrane Database Syst Rev. 2014;2014(9):CD007291.PubMedCentral
20.
LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995;31(5):1049–91.
21.
Late effects consensus conference. RTOG/EORTC. Radiother Oncol. 1995;35:5–7.CrossRef
22.
Feldmann B, Schneider H, Klinkers A. A multivariate approach for the biometric of comparison analytical methods in clinical chemistry. J Clin Chem Clin Biochem. 1981;19:121–37.PubMed
23.
Lauwrence I, Lin K. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255–68.CrossRef
24.
Sabater S, Andres I, Lopez-Honrubia V, Berenguer R, Sevillano M, Jimenez-Jimenez E, et al. Vaginal cuff brachytherapy in endometrial cancer—a technically easy treatment? Cancer Manag Res. 2017;9(9):351–62.CrossRef
25.
Matulonis UA, Virginia L, et al. Analysis of patient-reported outcomes (PROs) for GOG-258, a randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel (Cis-RT+CP) vs. carboplatin and paclitaxel (CP) for optimally debulked, locally advanced endometrial carcinoma: a gynecologic oncology group/NRG study. J Clin Oncol. 2018;36(suppl. 15):5589.CrossRef
26.
Matei D, Filiaci VL, Randall M. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. Proc Am Soc Clin Oncol. 2017;35 (abstr 5505). Gynecol Oncol 2016;134:48.
27.
de Boer SM, Powell ME, Mileshkin L, et al. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:1114–26.CrossRef
28.
Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Lederman J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Radiother Oncol. 2015;117:559–81.CrossRef
29.
Lee SW, Lee TS, Hong DG, No JH, Park DC, Bae JM, et al. Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. J Gynecol Oncol. 2017;28(1):e12.CrossRef
30.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Uterine NeoplasmsVersion 2.2019—December 17, 2018ContinueNCCN Guidelines for Patients®. www.​nccn.​org
31.
Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K. Interdisciplinary diagnosis therapy and follow-up of patients with endometrial cancer. Guideline (S3-Level, AWMF registry number 032, 034-OL, April 2018—Part 2 with recommendations on the therapy and follow-up of endometrial cancer, palliative care, psycho-oncological/psychosocial care/ rehabilitation/patient information and healthcare facilities. Geburtsh Frauenheilk. 2018;78:1089–109.CrossRef
32.
Small W Jr, Erickson B, Kwakwa F. American Brachytherapy Society survey regarding practice patterns of postoperative irradiation for endometrial cancer: current status of vaginal brachytherapy. Int J Radiat Oncol Biol Phys. 2005;63(5):1502–7.CrossRef
33.
Cozad SC. Stage II adenocarcinoma of the endometrium:adjuvant radiotherapy and recurrence patterns. Int Radiat Oncol Biol Phys. 2008;1(71):205–12.CrossRef
34.
Herrera G, Cruz OS, Achtari C, Bourhis J, Ozsahin M. Long-term outcome and late side effects in endometrial cancer patients treated with surgery and postoperative radiation therapy. Ann Surg Oncol. 2014;21:2390.CrossRef
35.
Aguilera M, Rovirosa A, Ascaso C, Herreros A, Sánchez J, Garcia-Migue J, et al. Late G2 vagina toxicity in postoperative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2Gy per fraction(α/β=3Gy) at 2 cm3 of vagina. J Contemp Brachyther. 2018;10(1):40–6.CrossRef
36.
Jhingran A, Winter K, Portelance L, Miller B, Salehpour M, Gaur R, et al. A phase II study of intensity modulated radiation therapy (IMRT) to the pelvic for post-operative patients with endometrial carcinoma (RTOG 0418). Int J Radiat Oncol Biol Phys. 2012;84(1):e23–e2828.CrossRef
37.
Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, et al. A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015;121(13):2156–63.CrossRef
38.
Rovirosa A, Herreros A, Ascaso C, Sola J, Huguet A, Garridos S, et al. Economic impact of decreasing the number of fractions in postoperative brachytherapy of endometrial carcinoma by one third ASTRO 2018 ASTRO meeting. Int J Radiat Oncol Biol Phys. 2018;102(3):TU-4-2937.E400.CrossRef
Metadata
Title
Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?
Authors
Y. Zhang
C. Ascaso
A. Herreros
J. Sánchez
M. del Pino
A. Torné
Y. Li
S. Sabater
M. Arenas
A. Biete
Á. Rovirosa
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02255-z

Other articles of this Issue 8/2020

Clinical and Translational Oncology 8/2020 Go to the issue

Correspondence

TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)

Brief Research Article

Current functioning of cardio-oncology units in Spain

Research Article

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Review Article

An overview of yeast probiotics as cancer biotherapeutics: possible clinical application in colorectal cancer

Research Article

Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population

Research Article

Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits